Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
- Authors
- Type
- Published Article
- Journal
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press
- Publication Date
- Aug 13, 2020
- Volume
- 7
- Issue
- 9
- Identifiers
- DOI: 10.1093/ofid/ofaa356
- PMID: 32965277
- PMCID: PMC7491710
- Source
- PubMed Central
- Keywords
- License
- Unknown
Abstract
The DUALIS phase-III study demonstrated non-inferiority of an effective and safe switch to dolutegravir combined with boosted darunavir (2DR) in suppressed people living with HIV as compared to continue 2 nucleoside reverse transcriptase inhibitors in combination with boosted darunavir (3DR).